A Phase 2, Open-label Study of ABI-009 (Nab-Rapamycin) in Bevacizumab-Naïve Subjects With Progressive High Grade Glioma Following Prior Therapy and Subjects With Newly Diagnosed Glioblastoma
Phase of Trial: Phase II
Latest Information Update: 11 Dec 2019
Price : $35 *
At a glance
- Drugs Sirolimus (Primary) ; Bevacizumab; Lomustine; Marizomib; Temozolomide
- Indications Glioblastoma; Glioma
- Focus Therapeutic Use
- Sponsors AADi
- 07 Dec 2019 Planned primary completion date changed from 1 Jun 2020 to 1 Dec 2020.
- 29 Aug 2018 Status changed from not yet recruiting to recruiting.
- 15 Mar 2018 New trial record